TABLE 1.
Clinicopathologic Patient Characteristics
| Characteristic | n |
|---|---|
| Sex | |
| Female | 17 (52%) |
| Male | 16 (48%) |
| Age group | |
| <65 y | 17 (52%) |
| ≥65 y | 16 (48%) |
| Primary site of origin | |
| Gastrointestinal | 21 (64%) |
| Pancreatic | 6 (18%) |
| Other sites | 2 (6%) |
| Unknown | 4 (12%) |
| Grade | |
| 1 | 14 (43%) |
| 2 | 16 (48%) |
| 3 | 1 (3%) |
| Unknown | 2 (6%) |
| Pre-PRRT treatment | |
| Somatostatin receptor analogs | 32 (97%) |
| Surgery | 15 (45%) |
| Chemotherapy | 8 (24%) |
| Locoregional | 2 (6%) |
| Radiotherapy/90Y-PRRT | 4 (12%) |
| Sunitinib or everolimus | 3 (9%) |
| Sites of metastasis | |
| Liver | 31 (94%) |
| Bone | 18 (55%) |
| Lymph nodes | 24 (72%) |
| Peritoneum | 8 (24%) |
| Risk factors for renal toxicity | |
| Hypertension | 18 (22%) |
| Diabetes | 9 (17.6%) |
| Chemotherapy | 8 (24%) |
| 90Y-PRRT | 3 (6%) |
| Number of 177Lu cycles | |
| <4 | 7 (21%) |
| 4 | 26 (79%) |